GNI Group Ltd. (TYO:2160)
Japan · Delayed Price · Currency is JPY 2,680.00
+47.00 (1.79%)
Aug 6, 2026, 9:54 AM JST
GNI Group Financials Overview
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 27,046 | 26,840 | 23,611 | 26,010 | 17,418 | 12,690 |
Revenue Growth | 17.67% | 13.68% | -9.22% | 49.33% | 37.26% | 29.85% |
Gross Profit Gross Profit Growth | 19,902 | 19,993 | 18,036 | 22,430 | 14,744 | 11,089 |
Operating Income Operating Income Growth | -5,461 | -2,503 | 1,559 | 4,506 | 1,170 | 1,029 |
Net Income Net Income Growth | -6,008 | -4,244 | 1,098 | 8,094 | 388 | 1,066 |
Earnings Per Share EPS Growth | -111.60 | -80.90 | 21.15 | 165.56 | 8.11 | 22.08 |
EPS Growth | - | - | -87.22% | 1941.43% | -63.27% | -21.25% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Pharmaceutical Pharmaceutical Growth | 19,212 | 19,158 | 18,304 | 22,976 | 14,991 | 10,895 |
Medical Device Medical Device Growth | 7,834 | 7,681 | 5,308 | 3,059 | 2,521 | 1,919 |
Total Total Growth | 27,046 | 26,839 | 23,612 | 26,011 | 17,419 | 12,690 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 19,869 | 21,101 | 10,115 | 21,633 | 11,049 | 14,352 |
Total Debt Total Debt Growth | 5,171 | 5,365 | 7,205 | 3,699 | 536 | 1,125 |
Net Cash (Debt) Net Cash Growth | 14,698 | 15,736 | 2,910 | 17,934 | 10,513 | 13,227 |
Net Cash Growth | 344.14% | 440.76% | -83.77% | 70.59% | -20.52% | 54.23% |
Net Cash Per Share Net Cash Per Share Growth | 272.98 | 299.93 | 56.05 | 366.82 | 219.34 | 273.91 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -2,536 | -2,408 | -3,164 | 6,549 | 393 | 552 |
Capital Expenditures CapEx Growth | -393 | -334 | -523 | -1,273 | -973 | -379 |
Free Cash Flow Free Cash Flow Growth | -2,929 | -2,742 | -3,687 | 5,276 | -580 | 173 |
Free Cash Flow Growth | - | - | - | - | - | -83.88% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 73.59% | 74.49% | 76.39% | 86.24% | 84.65% | 87.38% |
Operating Margin | -20.19% | -9.33% | 6.60% | 17.32% | 6.72% | 8.11% |
Pretax Margin | -25.86% | -17.27% | 1.01% | 48.49% | 4.40% | 8.72% |
Profit Margin | -22.21% | -15.81% | 4.65% | 31.12% | 2.23% | 8.40% |
FCF Margin | -10.83% | -10.22% | -15.62% | 20.29% | -3.33% | 1.36% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 6, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 155.51 | 17.39 | 170.49 | 65.94 |
Forward PE | - | 26.78 | 15.05 | 76.49 | 47.70 | 28.90 |
P/FCF Ratio | - | - | - | 26.67 | - | 406.31 |
PS Ratio | 6.41 | 5.00 | 7.23 | 5.41 | 3.80 | 5.54 |